263 related articles for article (PubMed ID: 37491889)
21. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
22. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
23. Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
Hao Z; Sekkath Veedu J
Clin Lung Cancer; 2022 Jan; 23(1):14-20. PubMed ID: 34656433
[TBL] [Abstract][Full Text] [Related]
24. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Jo U; Senatorov IS; Zimmermann A; Saha LK; Murai Y; Kim SH; Rajapakse VN; Elloumi F; Takahashi N; Schultz CW; Thomas A; Zenke FT; Pommier Y
Mol Cancer Ther; 2021 Aug; 20(8):1431-1441. PubMed ID: 34045232
[TBL] [Abstract][Full Text] [Related]
25. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
26. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract][Full Text] [Related]
29. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
30. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
32. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E; Sessa C; Harada G; de Miguel M; Kahatt C; Luepke-Estefan XE; Siguero M; Fernandez-Teruel C; Cullell-Young M; Stathis A; Drilon A
Invest New Drugs; 2022 Dec; 40(6):1263-1273. PubMed ID: 35947247
[TBL] [Abstract][Full Text] [Related]
34. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
35. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
[TBL] [Abstract][Full Text] [Related]
36. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
[No Abstract] [Full Text] [Related]
37. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
38. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
39. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Fernández-Teruel C; Fudio S; Lubomirov R
Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
